Figure 1.
Post hoc estimates of individual patient's lamotrigine clearance (CL) with the base population model according to co‐treatment with inhibitors of metabolism (A: None,
Sertraline,
Valproic acid), inducers (B:
None,
Carbamazepine,
Phenobarbital,
Phenytoin), cigarette smoking (C), ABCB1 2677G > C/A genotype (D), UGT2B7–161C > T genotype (E) and UGT2B7 372 A > G genotype (F)